StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

LALPATHLAB — DR. LAL PATH LABS LTD.

Structural concernsInstitutions reducing stake

Price History

Data as of 26 Jun 2026· via fincrux

How LALPATHLAB has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Upper end of its 12-month range92% of range

Trading about 29% above its 12-month low and near recent highs — historically pricier territory for this stock. It sits above its 200-day average, the longer-term trend.

₹1,304 low₹1,724 high
vs 50-day avg
+7.9%
vs 200-day avg
+13.1%
Beginner mode
Plain English, with everything explained

LALPATHLAB

NSE

DR. LAL PATH LABS LTD.

Healthcare / Diagnostics

₹1,689.20
0.00%
last close
0%
Quality Score
A mixed pictureBig money selling

DR. LAL PATH LABS LTD. passes 2 of 3 checks. There's something to like here, but also a few things to be careful about. Read the four checks below before forming a view.

Company size
₹26946.00 Cr
Price tag
50.7×
Money it earns
23.1%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.08goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Aligned

It turns its money into healthy profits year after year. A hallmark of a quality business.

ROE 23.1%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Divergent

Professional investors have been reducing their stake recently.

FII+DII 38.6%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnost…
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What LALPATHLAB owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings38528114253193
Equity Capital83838384168
Reserves1,3891,6061,7172,0512,305
Total Assets2,2112,3202,3492,6213,049
Total Liabilities2,2112,3202,3492,6213,049

Borrowings trending down

Total borrowings are down about 50% over the last 5 years — the company has been reducing its reliance on debt.

Periodic Performance

Yearly net profit for LALPATHLAB — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

Profit dipped in the middle years and has been recovering in the most recent ones. That's a pattern in the data, not a forecast.

₹345 Cr
₹292 Cr
₹347 Cr
₹497 Cr
₹508 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹1,879 Crrev ₹1,769 Crrev ₹2,125 Crrev ₹2,352 Crrev ₹2,648 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about LALPATHLAB — observations, not recommendations.

Strengths

3
  • Turns owners' money into healthy profits, year after year.
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.

Risks

2
  • Large professional investors have been trimming their stake recently.
  • Sits near the top of its 12-month range — historically pricier territory for this stock.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
17.2%-4.5 pp
DII· Domestic institutions
21.4%+3.8 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Diagnostics score on the same four guardrails.

  • METROPOLISMETROPOLIS HEALTHCARE LTD66
View the full sector